The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials.
 
Koji Oba
Honoraria - Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Eisai; Ono Pharmaceutical; Takeda
 
Xavier Paoletti
Consulting or Advisory Role - MSD Oncology
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; GlaxoSmithKline; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Olivier Bouché
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Roche
Speakers' Bureau - Amgen; Pierre Fabre; Sanofi; Servier
Travel, Accommodations, Expenses - Merck Serono; Roche; Servier
 
Michel Ducreux
Employment - Sandoz (I)
Honoraria - Amgen; Bayer; Celgene; Ipsen; Lilly; Merck Serono; MSD Oncology; Novartis; Roche/Genentech; Servier
Consulting or Advisory Role - Amgen; Celgene; HalioDx; Ipsen; Lilly; Merck Serono; Novartis; Pierre Fabre; Roche; Servier
Speakers' Bureau - Bayer; Celgene; Ipsen; Merck KGaA; Roche
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Ipsen; Merck Serono; Roche
 
Stefan Michiels
Consulting or Advisory Role - Biophytis; Hexal; IDDI; Janssen-Cilag; QuintilesIMS; Roche; Sensorion
Patents, Royalties, Other Intellectual Property - Co-inventor of patent WO2018002385A1 on prognostic gene score in early breast cancer
 
Markus H. Moehler
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly/ImClone; Merck Serono; MSD Oncology; Roche/Genentech; Servier; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck Serono; MSD; Nordic Group; Pfizer; Roche; SERVIER; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jennerex (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; ESMO; German Cancer Society; Merck Serono; MSD; Roche
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Nippon Boehringer Ingelheim (Inst)
 
Yasuo Ohashi
Leadership - EP-Cruse Co., Ltd; EP-Techno; Statcom
Stock and Other Ownership Interests - Statcom
Honoraria - Chugai Pharma; Daiichi Sankyo; Kowa; Sanofi; Shionogi
Research Funding - Medical Members System (Inst)
 
Junichi Sakamoto
Honoraria - Chugai Pharma; Nippon Kayaku
Consulting or Advisory Role - Olympus Medical Systems; Takeda
 
Mitsuru Sasako
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Lilly Japan; Merck; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Olympus
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Marc E. Buyse
Employment - IDDI
Stock and Other Ownership Interests - IDDI
 
Tomasz Burzykowski
Employment - IDDI
Stock and Other Ownership Interests - IDDI